These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 28652928)
1. pH of anti-VEGF agents in the human vitreous: low impact of very different formulations. Sobolewska B; Heiduschka P; Bartz-Schmidt KU; Ziemssen F Int J Retina Vitreous; 2017; 3():22. PubMed ID: 28652928 [TBL] [Abstract][Full Text] [Related]
2. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007419. PubMed ID: 28639415 [TBL] [Abstract][Full Text] [Related]
3. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept. Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277 [TBL] [Abstract][Full Text] [Related]
4. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium. Schottler J; Randoll N; Lucius R; Caliebe A; Roider J; Klettner A Exp Eye Res; 2018 Jun; 171():1-11. PubMed ID: 29522724 [TBL] [Abstract][Full Text] [Related]
6. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB. Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709 [TBL] [Abstract][Full Text] [Related]
7. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration. Park DH; Sun HJ; Lee SJ Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933 [TBL] [Abstract][Full Text] [Related]
8. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab. Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA; JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655 [TBL] [Abstract][Full Text] [Related]
10. Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits. Cam D; Berk AT; Micili SC; Kume T; Ergur BU; Yilmaz O Curr Eye Res; 2017 Feb; 42(2):315-322. PubMed ID: 27314606 [TBL] [Abstract][Full Text] [Related]
11. Systemic Biodistribution and Intravitreal Pharmacokinetic Properties of Bevacizumab, Ranibizumab, and Aflibercept in a Nonhuman Primate Model. Christoforidis JB; Briley K; Binzel K; Bhatia P; Wei L; Kumar K; Knopp MV Invest Ophthalmol Vis Sci; 2017 Nov; 58(13):5636-5645. PubMed ID: 29094168 [TBL] [Abstract][Full Text] [Related]
12. Effects of bevacizumab, ranibizumab, and aflibercept on phagocytic properties in human RPE cybrids with AMD versus normal mitochondria. Vo TA; Abedi S; Schneider K; Chwa M; Kenney MC Exp Eye Res; 2018 Dec; 177():112-116. PubMed ID: 30071215 [TBL] [Abstract][Full Text] [Related]
13. Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept. Forooghian F; Albiani DA; Kirker AW; Merkur AB Can J Ophthalmol; 2017 Dec; 52(6):616-619. PubMed ID: 29217032 [TBL] [Abstract][Full Text] [Related]
14. Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept. de Oliveira Dias JR; de Andrade GC; Novais EA; Farah ME; Rodrigues EB Int J Retina Vitreous; 2016; 2():3. PubMed ID: 27847621 [TBL] [Abstract][Full Text] [Related]
15. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA. Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940 [TBL] [Abstract][Full Text] [Related]
16. Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry. Rao P; Lum F; Wood K; Salman C; Burugapalli B; Hall R; Singh S; Parke DW; Williams GA Ophthalmology; 2018 Apr; 125(4):522-528. PubMed ID: 29146306 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Stewart MW; Rosenfeld PJ; Penha FM; Wang F; Yehoshua Z; Bueno-Lopez E; Lopez PF Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154 [TBL] [Abstract][Full Text] [Related]